Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery) BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD)AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple scientific presentations at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 5-8 in Boston, Massachusetts. Presentations at Eyecelerator (associated @ ASCRS 2024):
Session Title: “Presenting Company Showcases”
Session Date/Time: Thursday, April 4th at 1 PM EST
Location: Omni Boston Hotel at the Seaport – Breakout 2
Presentations at ASCRS at the Boston Convention and Exhibition Center (BCEC)
Session Title: Glaucoma (Procedures and Medications) Session Date/Time: Saturday, April 6th at 10 AM EST
Location: Meeting Level 2, Room 257B
Presenter: Mark J. Gallardo, MD
Title: Incidence of Safety Events Following Cataract Surgery with Intracanalicular Dexamethasone: A Study of 50,000 Eyes Using the IRIS Registry Session Title: Medications (Preoperative, Postoperative, Intraoperative)
Session Date/Time: Sunday, April 7th at 3:50 PM EST
Location: Meeting Level 2, Room 257A
Presenter: Steven M. Silverstein, MD, FACS, ABO
Title: Characteristics of Cataract Surgery Patients Receiving Intracanalicular Dexamethasone Insert: An IRIS Registry Analysis of 50,000 Eyes
Session Title: Medications (Preoperative, Postoperative, Intraoperative)
Session Date/Time: Sunday, April 7th at 4:15 PM EST
Location: Meeting Level 2, Room 257A
Presenter: Nandini Venkateswaran, MD, ABO
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD)AMD), diabetic retinopathy, and other diseases and conditions of the eye, including glaucoma. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in the first of two planned pivotal Phase 3 trials for wet AMDAMD, the SOL-1 trial, and a Phase 1 clinical trial for the treatment of non-proliferative diabetic retinopathy. The clinical portfolio also includes PAXTRAVA™ (travoprost intracameral implant, also known as OTX-TIC), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension. Follow us on our website, LinkedIn or X.
Please see full Prescribing and Safety Information at the DEXTENZA website. jallaire@lifesciadvisors.com